Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer

Bangladesh Medical Research Council Bulletin

Volumn 38, Issue 3, 2012, Pages 90-93

  Rashid, M M ^a   Alam, A K M K ^a   Habib, A K M K ^a   Rahman, H ^a   Hossain, A K M S ^a   Salam, M A ^a   Rahman, S ^a  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION;

EID: 84876888924     PISSN: 03779238     EISSN: None     Source Type: Journal    
DOI: 10.3329/bmrcb.v38i3.14333     Document Type: Article

References (18)

1. Presti JC Jr., Tanagho EA. Disorders of bladder, prostate and seminal vesicles. In: Emil A Tanagho, Jack W McAninch [editors]: Smith's General Urology, 16th ed. New York: Lange medical book / McGraw Hill; 2004. 576-591.
2. Reiter RE, de Kernion JB. Epidemiology, etiology and prevention of prostate cancer. In: Walsh Patrick C, Retik Alan B, E Darracott Vaughan, Alan J Wein [editors]: Campbell's Urology. 8th ed. Philadelphia: Saunders; 2002: 3003-3024.
3. PolascikTJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery- What we have learned and where we are going. J Urol 2006; 162:293-306.
4. Vis AN, Kranse R, Roobol M, et al.: Serendipity in detecting disease in low prostate specific antigen ranges. BJU Int 2002; 89: 384-389.
5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 2005; 277:1452-1455.
6. Shekarriz B, Upadhyay J, Bianco FJ. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy. Prostate 2002; 48:136-143.
7. Babaian RJ, Johnston DA, Naccarato W. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165:757-760.
8. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ. Prostate cancer detection at low prostate specific antigen. J Urol 2002; 163:806-812.
9. Faria EF, Carvalhal GF, Vieira RA, Silva TB, Mauad EC, Carvalho AL. Program for prostate cancer screening using a mobile unit: results from Brazil. Urology. 2010 Nov; 76(5): 1052-7.
10. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005; 174: 2154-7.
11. Rahman S, Siddiq AB, Islam MS, Salam MA, Khan SA. A comparative study between TRUS guided 6 core and 12 core prostate biopsy for detection of prostate cancer. Bangladesh Journal of Urology. 2010 Jan; 13(1):14-20.
12. Deepak Dubey. The routine use of Prostate cancer antigen for early detection of prostate cancer in India: Is it justified? Indian Journal of Urology. 2009 April; 25(2): 177-184.
13. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002; 59: 889-93.
14. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate specific antigen. N Engl J Med. 2003; 349: 335-42.
15. Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. Urology 2005; 66: 1029-33.
16. Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 2005; 24: 333-338.
17. Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate-specific antigen level or=4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
18. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostatecancer screening results in American men. BJU Int. 2009 Nov. 104(10): 1457-61.